Bing

SEARCH HISTORY

Illumina (NASDAQ:ILMN) Director A Blaine Bowman sold 3,000 shares of the company’s stock in a transaction dated Friday, July 24th. The shares were sold at an average price of $221.47, for a total transaction of $664,410.00. Following the completion of ...
Mideast Times · 1 day ago
An earnings beat just wasn’t enough for Illumina today. The market sent ILMN stock more than 8% lower following the company reported second quarter sales that fell short of analyst estimates. The hunt Biogen is on …
Investor Place · ByJames Brumley · 7/22/2015
Trade-Ideas LLC identified Illumina ( ILMN) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Illumina as such a stock due to the following factors: ILMN has an average dollar-volume (as measured by ...
The Street · 7/21/2015
Illumina
More from Bing News
Illumina (NASDAQ:ILMN)‘s stock had its “buy” rating restated by analysts at BTIG Research in a research report issued to clients and investors on Friday, Marketbeat.com reports. A number of other firms have also recently commented on ILMN.
wkrb13.com · 7/19/2015
Gene-sequencing giant Illumina (NASDAQ:ILMN) beat analysts' Q2 earnings estimates Tuesday ... perhaps explaining why it didn't help the stock. Expectations seemed to be high going in, as the stock hit a new high …
Investors Business Daily · ByAmy Reeves · 7/21/2015
Illumina (NASDAQ:ILMN) Director David R. Walt sold 12,000 shares of the stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $235.24, for a total value of $2,822,880.00. Following the transaction, the ...
Ticker Report · 7/24/2015
Illumina (NASDAQ:ILMN) SVP Mostafa Ronaghi sold 1,200 shares of the company’s stock in a transaction dated Friday, July 17th. The shares were sold at an average price of $235.00, for a total value of $282,000.00. Following the completion of the sale …
sleekmoney.com · 7/22/2015
XOMA (NASDAQ: XOMA) 79% LOWER; Phase 3 EYEGUARD-B study of gevokizumab in patients with Bechet's disease uveitis, run by its partner Servier, did not meet the primary endpoint of time to first acute ocular …
StreetInsider · 7/22/2015
Illumina's (NASDAQ:ILMN) stock price reaction (-8%) following Q2 results is understandable. While rising investor expectations had sparked a more than 10% stock price pop in recent weeks, the company, for once, did not impress when it reported its ...
Seeking Alpha · 7/23/2015
Unchanged Confidence
In-depth coverage >
What's happening: Shares of the gene-sequencing company Illumina (NASDAQ:ILMN) dropped by as much as 11% today on heavy volume following the release of its second-quarter results after the bell yesterday. For …
The Motley Fool · 7/24/2015
Illumina Inc